VIATRIS INC. Business Acquisition, Pro Forma Net Income (Loss)
VIATRIS INC. (VTRS) reported Business Acquisition, Pro Forma Net Income (Loss) of $93.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-02-26
- VIATRIS INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-12-31 was -$759.10M, a 176.63% decline year-over-year.
- VIATRIS INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was $338.30M, a 7.84% increase year-over-year.
- VIATRIS INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was $270.60M, a 2.34% increase year-over-year.
- VIATRIS INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was $990.60M.
- VIATRIS INC. business acquisition, pro forma net income (loss) for fiscal 2023 was $93.80M, a 95.08% decline from fiscal 2022.
- VIATRIS INC. business acquisition, pro forma net income (loss) for fiscal 2022 was $1.91B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$759.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$420.80M derived: sum of 2 quarters · filed 2026-02-26 | -$150.20M derived: sum of 3 quarters · filed 2026-02-26 | $93.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $338.30M 10-Q · filed 2023-11-08 | $608.90M derived: sum of 2 quarters · filed 2023-11-08 | $852.90M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $270.60M 10-Q · filed 2023-08-07 | $514.50M 10-Q · filed 2023-08-07 | ||
| 2022-12-31 | $990.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.30B derived: sum of 2 quarters · filed 2025-02-27 | $1.57B derived: sum of 3 quarters · filed 2025-02-27 | $1.91B 10-K · filed 2025-02-27 |
| 2022-09-30 | $313.70M 10-Q · filed 2023-11-08 | $578.10M derived: sum of 2 quarters · filed 2023-11-08 | $915.10M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $264.40M 10-Q · filed 2023-08-07 | $601.40M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |